Stephens Reiterates Equal Weight Rating for Amedisys (NASDAQ:AMED)

Amedisys (NASDAQ:AMED - Get Free Report)'s stock had its "equal weight" rating reaffirmed by stock analysts at Stephens in a report issued on Tuesday,Benzinga reports. They presently have a $101.00 price target on the health services provider's stock. Stephens' target price points to a potential upside of 9.34% from the company's current price.

Amedisys Stock Up 0.2 %

AMED traded up $0.20 on Tuesday, hitting $92.37. 168,386 shares of the company were exchanged, compared to its average volume of 377,405. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. The stock's fifty day moving average is $91.95 and its 200-day moving average is $93.04. The company has a market cap of $3.03 billion, a PE ratio of 36.65, a PEG ratio of 1.78 and a beta of 0.73. Amedisys has a 12 month low of $82.15 and a 12 month high of $98.95.

Amedisys (NASDAQ:AMED - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The health services provider reported $0.96 EPS for the quarter, missing the consensus estimate of $1.05 by ($0.09). Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The company had revenue of $598.05 million during the quarter, compared to analyst estimates of $602.38 million. Equities research analysts predict that Amedisys will post 4.4 EPS for the current fiscal year.

Remove Ads

Institutional Investors Weigh In On Amedisys

Several hedge funds have recently bought and sold shares of the company. Norges Bank bought a new stake in Amedisys in the fourth quarter valued at approximately $83,061,000. Wealthfront Advisers LLC acquired a new position in shares of Amedisys during the 4th quarter worth approximately $72,970,000. Pentwater Capital Management LP raised its stake in Amedisys by 178.3% in the 4th quarter. Pentwater Capital Management LP now owns 1,180,000 shares of the health services provider's stock valued at $107,132,000 after acquiring an additional 756,000 shares during the period. Pacer Advisors Inc. raised its stake in Amedisys by 11,621.9% in the 4th quarter. Pacer Advisors Inc. now owns 558,197 shares of the health services provider's stock valued at $50,679,000 after acquiring an additional 553,435 shares during the period. Finally, Polar Asset Management Partners Inc. acquired a new stake in Amedisys during the 3rd quarter valued at $28,953,000. 94.36% of the stock is currently owned by institutional investors and hedge funds.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.